Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2013 Oct;33(10):4631-7.

Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.

Author information

  • 11-5-34, Otemae, Chuo-ku, Osaka, 540-0008, Japan. kawaharam@otemae.gr.jp.

Abstract

AIM:

Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS:

Chemotherapy-naïve patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m(2)) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m(2)) plus carboplatin (same dose), on day 1 every 21 days. The primary end-point was progression-free survival (PFS).

RESULTS:

A total of 90 patients were enrolled. Overall response rate, median PFS and median survival time in the docetaxel-plus-carboplatin group and the paclitaxel-plus-carboplatin group were 23% vs. 33%, 4.8 months vs. 5.1 months, and 17.6 months vs. 15.6 months, respectively. The docetaxel-plus-carboplatin group had a higher incidence of grade 3 or 4 neutropenia (88% vs. 60%).

CONCLUSION:

Both regimens were similarly effective in Japanese patients with advanced NSCLC.

KEYWORDS:

Non-small cell lung cancer; chemotherapy; docetaxel; ethnicity; paclitaxel carboplatin; randomized phase 2

PMID:
24123041
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk